

Managed Care Considerations in Meeting the Complex Needs of Patients With Pancreatic Cancer

Release date: January 9, 2019
Expiration date: January 9, 2020

Pharmacy Credit

Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information

This lesson is free online; receive instant grading and request your CE credit at www.PharmacyTimes.org.

Testing and Grading Directions

1. Each participant evaluating the activity is eligible to receive CE credit.
2. To receive your credit online, go to www.PharmacyTimes.org and complete the online posttest and the online activity evaluation form before the expiration date. Your CE credit will be automatically uploaded to CPE Monitor. Please ensure that your *Pharmacy Times*[®] account is updated with your NABP e-profile ID number and your date of birth (MMDD format). Participation data will *not* be uploaded into CPE Monitor if you do not have your NABP e-profile ID number and date of birth entered into your profile on www.PharmacyTimes.org.

Sample of Online Posttest

Choose the best answer for each of the following:

1. **What is the most appropriate treatment option for a 70-year-old patient with stage IV pancreatic adenocarcinoma, with Eastern Cooperative Oncology Group performance status 2 and mild hepatic insufficiency?**
 - A. FOLFIRINOX
 - B. Nab-paclitaxel/gemcitabine
 - C. Liposomal irinotecan/5-fluorouracil/leucovorin
 - D. Gemcitabine/pembrolizumab
2. **Which of the following criterion was a key element in the trial that demonstrated use of olaparib for the treatment of metastatic pancreatic cancer?**
 - A. Germline *BRCA1/2* mutation
 - B. Prior erlotinib therapy
 - C. Microsatellite instability–low
 - D. Overexpression of PD-L1
3. **What is the mechanism of action of pegylated hyaluronidase?**
 - A. Degrades hyaluronan, which is a component of the tumor stroma, and grants greater access of chemotherapy to the tumor cells
 - B. Inactivates chemokines (CCR2, CCR5) involved in stimulating growth of tumor cells
 - C. Degrades hyaluronan, which competitively blocks gemcitabine from uptake into cells by nucleoside transporters
 - D. Inactivates molecules that downregulate cytotoxic T cells located within tumors
4. **Which of the following toxicities is most associated with the administration of liposomal irinotecan?**
 - A. Febrile neutropenia
 - B. QT prolongation
 - C. Pneumonitis
 - D. Hepatic failure
5. **When is the most appropriate time to discuss palliative care with a patient diagnosed with pancreatic cancer?**
 - A. At the time of diagnosis
 - B. After progression of first line of chemotherapy
 - C. After progression of second line of chemotherapy
 - D. When all lines of therapy have been exhausted
6. **Mean per-member, per-month total costs for patients with pancreatic cancer versus matched controls are approximately:**
 - A. 2 times higher
 - B. 10 times higher
 - C. 15 times higher
 - D. 20 times higher
7. **Economic analyses comparing FOLFIRINOX to nab-paclitaxel/gemcitabine in first-line therapy for metastatic pancreatic cancer found:**
 - A. Higher total treatment costs with FOLFIRINOX
 - B. Higher total treatment costs with nab-paclitaxel/gemcitabine
 - C. No difference between the 2 regimens
 - D. Higher costs of therapy than survival gains
8. **Assuming an incremental cost-effectiveness ratio of \$100,000 as the willingness-to-pay threshold, which of the following is true regarding FOLFIRINOX and nab-paclitaxel/gemcitabine?**
 - A. Compared with gemcitabine, FOLFIRINOX is cost-effective.
 - B. Compared with gemcitabine, nab-paclitaxel/gemcitabine is cost-effective.
 - C. Compared with nab-paclitaxel/gemcitabine, FOLFIRINOX is cost-effective.
 - D. Neither regimen reaches the threshold level for cost-effectiveness when compared with gemcitabine.

9. A common approach to managing the cost of the treatment of pancreatic cancer care is:

- A. Requiring a biosimilar for first-line therapy when used in pancreatic cancer
- B. Implementing site-of-care programs
- C. Requiring prior authorization before beginning chemotherapy
- D. Using partial-fill programs

10. Under which program do clinicians receive case-management fees and possibly earn bonuses?

- A. Outcome-based payments
- B. Oncology Care Model
- C. Palliative Care Model
- D. Bundled payments

**SAMPLE
POSTTEST**